<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00339040</url>
  </required_header>
  <id_info>
    <org_study_id>P1047</org_study_id>
    <secondary_id>10163</secondary_id>
    <secondary_id>PACTG P1047</secondary_id>
    <nct_id>NCT00339040</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children</brief_title>
  <official_title>Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of and immune response to a new human
      papillomavirus (HPV) vaccine in HIV (Human immunodeficiency virus) infected children between
      the ages of 7 and 12 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Genital HPV infection is the most common sexually transmitted infection in the world and may
      lead to genital warts, anogenital dysplasias, and invasive cancers. HIV infected people and
      others with compromised immunity are at greater risk for HPV-related complications. In
      particular, researchers are concerned about the risk of HPV infection to women, who may be
      infected by their male partners, especially if these partners engage in anal intercourse. HIV
      infected women tend to have multiple types of HPV (associated with a greater risk of
      HPV-related disease), are less likely to clear HPV-related conditions, and are more likely to
      progress to HPV-related disease. The quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like
      particle (VLP) vaccine to be tested in this study was safe and generally well tolerated in
      previous studies conducted in healthy and HPV-exposed adolescents, young adults, and older
      women. However, it is still unclear if the vaccine will be safe and will elicit a similar
      immune response in younger children. The purpose of this study is to evaluate the safety and
      immunogenicity of the novel quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP vaccine in HIV
      infected children 7 to 12 years of age.

      This study had two stages and lasted at least 108 weeks. In Stage I, participants were
      stratified by CD4 percentage (CD4%) nadir and CD4% at study screening (Stratum A: CD4% Nadir
      &lt; 15 and CD4% ≥ 15 at screening, Stratum B: CD4% Nadir ≥ 15 and &lt; 25 and CD4% ≥ 15 at
      screening, Stratum C: CD4% Nadir ≥ 25 and CD4% ≥ 25 at screening). Within each stratification
      group, they were randomly assigned to one of two arms. During Stage I, Arm A
      (QHPV:Quadrivalent human papillomavirus vaccine) participants received 3 doses of vaccine,
      while Arm B (Placebo/QHPV) participants received 3 doses of placebo. Participants did not
      know whether they were receiving vaccine or placebo. Participants received their assigned
      intervention at study entry and Weeks 8 and 24. At Week 96, Stage II began, and all study
      participants were told if they received vaccine or placebo in Stage I. Arm A participants
      received an additional dose of vaccine at Week 96; Arm B participants received doses of
      vaccine at Weeks 96, 104, and 120. Over the course of the study, there were at least 12 study
      visits. A physical exam and blood collection occurred at most visits; medical history
      occurred at selected visits.

      After each vaccination, participants were observed for at least 30 minutes to monitor for any
      allergic reactions possibly resulting from the vaccination. For 15 days following
      vaccination, parents or guardians were asked to complete a &quot;report card&quot; with details of each
      child's signs and symptoms. Three days after each vaccination, parents or guardians of study
      participants were contacted by telephone and asked about any adverse events that a child may
      have experienced.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs)</measure>
    <time_frame>Within 14 days of first three doses of vaccination</time_frame>
    <description>Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004). The grades used are: Grade 1=&quot;Mild&quot;, Grade 2=&quot;Moderate&quot;, Grade 3=&quot;Severe&quot;, Grade 4=&quot;Potentially Life-Threatening&quot;. All grade 3 and higher signs, symptoms, and laboratory toxicities were included.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) Attributed to Study Treatment</measure>
    <time_frame>Within 14 days of first three doses of vaccination</time_frame>
    <description>Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities attributed to study treatment were included. The relationship between the Adverse Events and the vaccination were evaluated by study team and assigned to, for example, &quot;Treatment related&quot;, &quot;Non-treatment related&quot;, &quot;Baseline&quot;, &quot;Possibly treatment related&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With Human Papillomavirus (HPV) Type-Specific Seroconversion</measure>
    <time_frame>At week 28 after beginning the vaccination series</time_frame>
    <description>Serum anti-HPV 6, 11, 16, and 18 antibody was measured using a competitive Luminex immunoassay (cLIA; reported in milli-Merck Units [mMU]/mL). Sero-positivity was defined as an anti-HPV titer ≥20, 16, 20, and 24 mMU/mL, for HPV types 6, 11, 16, and 18, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Anti-HPV Antibody Titers (cLIA)</measure>
    <time_frame>Arm A week 0, 28, 72, 96, 97, 100; Arm B week 0, 28, 72, 96, 97, 100, 124.</time_frame>
    <description>Geometric means of Type-specific Serum anti-HPV antibody titers (cLIA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 Count Over Time</measure>
    <time_frame>Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Percent Over Time</measure>
    <time_frame>Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 Viral Load (Ribonucleic Acid [RNA] Copies/ml) Over Time</measure>
    <time_frame>Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>HIV Infections</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <arm_group>
    <arm_group_label>Arm A: QHPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QHPV at week 0, 8, 24, 96.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo/QHPV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)</intervention_name>
    <description>QHPV at week 0, 8, 24 and 96.</description>
    <arm_group_label>Arm A: QHPV</arm_group_label>
    <other_name>QHPV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo/QHPV</intervention_name>
    <description>Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.</description>
    <arm_group_label>Arm B: Placebo/QHPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Children ages ≥ 7 to &lt; 12 years of age.

        A confirmed diagnosis of HIV infection, defined as two positive assays from two different
        samples. The two results may be in any combination of the following:

          -  at any age: Deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), Ribonucleic
             acid (RNA) PCR

          -  age &gt; 4 weeks: p24 antigen detection

          -  age &gt;18 months: licensed ELISA (Enzyme-linked immunosorbent assay) with confirmatory
             Western Blot

        CD4% ≥ 15 at the time of screening is required (Note that this is a minimum requirement,
        and that for Stratum C the CD4% needs to be ≥ 25).

        For Strata A and B: Currently stable (≥ 3 months) on highly active antiretroviral therapy
        (HAART) regimen, defined as three or more antiretrovirals from at least two different
        therapeutic classes, or therapy with the combination of azidothymidine, lamivudine, and
        abacavir.

        For stratum C no antiretroviral therapy is required.

        Parent or legal guardian able and willing to provide signed informed consent.

        Negative urine pregnancy test sensitive to 25 International Unit (IU) beta-human chorionic
        gonadotropin (HCG) for girls who are menstruating (child bearing potential).

        Female study volunteers who are participating in sexual activity that could lead to
        pregnancy must agree to use two reliable methods of contraception, one of which must be a
        barrier method. A barrier method of contraception (condoms or cervical cap) together with
        another reliable form of contraception (condoms a , with a spermicidal agent; a diaphragm
        or cervical cap with spermicide; an intrauterine device [IUD]; or hormonal-based
        contraception) must be used while on this study. Condoms are recommended because their
        appropriate use is the only contraception method effective for preventing HIV-1
        transmission

        Males participating in the study must not attempt to impregnate a woman, or participate in
        sperm donation programs. Males engaging in sexual activity that could lead to pregnancy
        must use a condom.

        Exclusion Criteria

        Body temperature ≥ 101 F or ≥ 38.3 C, orally determined, within 72 hours prior to the first
        and each subsequent injection. Subjects may be vaccinated any time in the next seven days
        thereafter, provided that the site investigator is satisfied that the febrile illness has
        ended.

        Total bilirubin ≥ 5 x Upper Limit of Normal (ULN) at screening.

        Alanine transaminase (ALT) or serum glutamic pyruvic transaminase (SGPT) ≥ 5 x ULN at
        screening in the absence of other explained causes (as determined by the site investigator)
        at screening.

        Serum creatinine ≥ 1.5 mg/dL at screening.

        Absolute neutrophil count ≤ 750 cells/mm3 at screening.

        Hemoglobin ≤ 9.9 g/dL at screening.

        Platelet count ≤ 75,000 cells/mm³ at screening.

        Presence of an acute opportunistic non-bacterial or bacterial infection requiring therapy
        at the time of enrollment; the subject may be entered once he/she is stable on appropriate
        anti-infective therapy.

        Chemotherapy for active malignancy.

        Other known or suspected disease of the immune system, or immunosuppressive therapy.

        Prior treatment with immunosuppressive or immunomodulation therapy within 60 days of
        screening.

        Prior treatment with three or more week-long courses of corticosteroids (≥ 2.0 mg/kg or ≥
        20 mg total of prednisone-equivalent) within one year of screening; or any systemic (oral
        or parenteral) steroids (≥ 2.0 mg/kg or ≥ 20 mg total of prednisone-equivalent for ≥ 3
        days) within 30 days of study entry.

        Prior vaccinations with inactivated vaccines received within two weeks of any dose of study
        vaccine, and no other vaccinations may be planned for two weeks after each dose of study
        vaccine.

        Prior vaccinations with live vaccines received within three weeks before any dose of study
        vaccine, and no other vaccinations may be planned for two weeks after each dose of study
        vaccine.

        Prior diagnosis of sexually transmitted infections (STIs), genital warts, or juvenile
        recurrent papillomatosis.

        History of any severe allergic reaction (e.g., swelling of the mouth and throat, difficulty
        breathing, hypotension, or shock) that required medical intervention.

        Known allergies to any vaccine component, including aluminum, yeast, or BENZONASE™
        (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]).

        Previous treatment with any immune globulin preparation or blood-derived products within
        the six months prior to the first injection and none may be planned during the study.

        Known coagulation disorder that would contraindicate Intramuscular (IM) injections.

        Any clinically significant diseases (other than HIV infection) or clinically significant
        findings during the screening medical history or physical examination that, in the
        investigator's opinion, would compromise the outcome of this study.

        Breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron J. Levin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pediatric Infectious Diseases Section, University of Colorado Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's Hosp. Long Beach CA NICHD CRS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp. of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Mother-Child-Adolescent Program CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of California San Francisco NICHD CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Colorado Denver NICHD CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Med. Ctr.</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Med. Ctr. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida CDTC Ft Lauderdale NICHD CRS</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Florida Jacksonville NICHD CRS</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami Ped. Perinatal HIV/AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens &amp; Childrens HIV Program</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Cook County Hosp. Chicago NICHD CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp. of Boston NICHD CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center Ped. HIV Program NICHD CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WNE Maternal Pediatric Adolescent AIDS CRS</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan NICHD CRS</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers - New Jersey Medical School CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Med. Ctr. Bronx NICHD CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyu Ny Nichd Crs</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Memorial Hospital Rochester NY NICHD CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook NICHD CRS</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC Ped. CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude/UTHSC CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp. CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, Jansen KU, Allende M, Taddeo FJ, Skulsky D, Barr E. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine. 2004 Aug 13;22(23-24):3004-7.</citation>
    <PMID>15297048</PMID>
  </reference>
  <reference>
    <citation>Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R, Suhr G, Barr E, Dicello A, Li W, Smith JF, Tadesse A, Jansen KU. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine. 2004 Jul 29;22(21-22):2936-42.</citation>
    <PMID>15246630</PMID>
  </reference>
  <reference>
    <citation>Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF, Bryan JT, Cavanaugh PF Jr, Jansen KU, Barr E. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc. 2005 May;80(5):601-10.</citation>
    <PMID>15887427</PMID>
  </reference>
  <results_reference>
    <citation>Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, Radley DR, Esser MT, Weinberg A; IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010 Oct;55(2):197-204. doi: 10.1097/QAI.0b013e3181de8d26.</citation>
    <PMID>20574412</PMID>
  </results_reference>
  <results_reference>
    <citation>P1047 ORAL PRESENTATION at the 25th International Papillomavirus Conference May 8-14 2009, Malmö, Sweden given by Anna Barbara Moscicki. Safety and immunogenicity of Gardasil® in HIV-infected children. Moscicki AB, Weinberg A, Song LY, Handelsman E, Patterson J, Saah A, Radley D, Read JS, Sattler C and Levin MJ for IMPAACT P1047 team.</citation>
  </results_reference>
  <results_reference>
    <citation>Weinberg A, Song LY, Handelsman E, Moscicki AB, Patterson J, Saah A, Radley D, Esser M, Read J, and Levin MJ for IMPAACT P1047 Team. The P1047 data up to week 28 have been analyzed and presented to 15th CROI as abstract and poster #619a: Safety and Immunogenicity of a Quadrivalent Vaccine to Prevent Human Papilloma Virus (HPV) in HIV-Infected Children: IMPAACT P1047.</citation>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <results_first_submitted>September 7, 2011</results_first_submitted>
  <results_first_submitted_qc>December 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2012</results_first_posted>
  <disposition_first_submitted>August 3, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 3, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 5, 2010</disposition_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between October 11, 2006 and November 22, 2006 130 participants were enrolled at 34 clinical sites from US &amp; Puerto Rico.</recruitment_details>
      <pre_assignment_details>Participants were stratified by CD4% criteria. Four participants were randomized but did not receive the study treatment. The study analyses were based on 126 participants who received the study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A QHPV</title>
          <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
        </group>
        <group group_id="P2">
          <title>Arm B Placebo/QHPV</title>
          <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1 at Week 0</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2 at Week 8</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3 at Week 24</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not able to attend clinic</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Stage II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 4 at Week 96</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 5 at Week 104</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 6 at Week 120</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not able to attend clinic</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closing</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A QHPV</title>
          <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
        </group>
        <group group_id="B2">
          <title>Arm B Placebo/QHPV</title>
          <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.0" spread="1.4"/>
                    <measurement group_id="B2" value="9.9" spread="1.3"/>
                    <measurement group_id="B3" value="9.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification groups</title>
          <description>STRATIFICATION: Participant were stratified by CD4% criteria into three strata:
Stratum A: CD4% Nadir &lt; 15 and CD4% ≥ 15 at screening
Stratum B: CD4% Nadir ≥ 15 and &lt; 25 and CD4% ≥ 15 at screening
Stratum C: CD4% Nadir ≥ 25 and CD4% ≥ 25 at screening</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stratum A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 count</title>
          <units>cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="868" spread="367"/>
                    <measurement group_id="B2" value="1013" spread="455"/>
                    <measurement group_id="B3" value="903" spread="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4%</title>
          <units>percentage of total lymphocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.9" spread="7.9"/>
                    <measurement group_id="B2" value="35.8" spread="8.6"/>
                    <measurement group_id="B3" value="34.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Log10(RNA)</title>
          <units>Log10(copies/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="0.9"/>
                    <measurement group_id="B2" value="2.6" spread="0.8"/>
                    <measurement group_id="B3" value="2.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RNA group</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>401 to ≤5000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;5000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs)</title>
        <description>Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004). The grades used are: Grade 1=&quot;Mild&quot;, Grade 2=&quot;Moderate&quot;, Grade 3=&quot;Severe&quot;, Grade 4=&quot;Potentially Life-Threatening&quot;. All grade 3 and higher signs, symptoms, and laboratory toxicities were included.</description>
        <time_frame>Within 14 days of first three doses of vaccination</time_frame>
        <population>Any participant who received at least one study vaccine/placebo were included in the safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A QHPV</title>
            <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
          </group>
          <group group_id="O2">
            <title>Arm B Placebo/QHPV</title>
            <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs)</title>
          <description>Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004). The grades used are: Grade 1=&quot;Mild&quot;, Grade 2=&quot;Moderate&quot;, Grade 3=&quot;Severe&quot;, Grade 4=&quot;Potentially Life-Threatening&quot;. All grade 3 and higher signs, symptoms, and laboratory toxicities were included.</description>
          <population>Any participant who received at least one study vaccine/placebo were included in the safety analysis.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="3.0" upper_limit="14.5"/>
                    <measurement group_id="O2" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) Attributed to Study Treatment</title>
        <description>Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities attributed to study treatment were included. The relationship between the Adverse Events and the vaccination were evaluated by study team and assigned to, for example, &quot;Treatment related&quot;, &quot;Non-treatment related&quot;, &quot;Baseline&quot;, &quot;Possibly treatment related&quot;.</description>
        <time_frame>Within 14 days of first three doses of vaccination</time_frame>
        <population>Any participant who received at least one study vaccine/placebo were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A QHPV</title>
            <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
          </group>
          <group group_id="O2">
            <title>Arm B Placebo/QHPV</title>
            <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) Attributed to Study Treatment</title>
          <description>Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities attributed to study treatment were included. The relationship between the Adverse Events and the vaccination were evaluated by study team and assigned to, for example, &quot;Treatment related&quot;, &quot;Non-treatment related&quot;, &quot;Baseline&quot;, &quot;Possibly treatment related&quot;.</description>
          <population>Any participant who received at least one study vaccine/placebo were included in the safety analysis</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Human Papillomavirus (HPV) Type-Specific Seroconversion</title>
        <description>Serum anti-HPV 6, 11, 16, and 18 antibody was measured using a competitive Luminex immunoassay (cLIA; reported in milli-Merck Units [mMU]/mL). Sero-positivity was defined as an anti-HPV titer ≥20, 16, 20, and 24 mMU/mL, for HPV types 6, 11, 16, and 18, respectively.</description>
        <time_frame>At week 28 after beginning the vaccination series</time_frame>
        <population>The type-specific results are reported for participants remaining after exclusion of those with protocol violations, unevaluable specimens, or the presence of type-specific sero-positive antibody at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A QHPV</title>
            <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
          </group>
          <group group_id="O2">
            <title>Arm B Placebo/QHPV</title>
            <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Human Papillomavirus (HPV) Type-Specific Seroconversion</title>
          <description>Serum anti-HPV 6, 11, 16, and 18 antibody was measured using a competitive Luminex immunoassay (cLIA; reported in milli-Merck Units [mMU]/mL). Sero-positivity was defined as an anti-HPV titer ≥20, 16, 20, and 24 mMU/mL, for HPV types 6, 11, 16, and 18, respectively.</description>
          <population>The type-specific results are reported for participants remaining after exclusion of those with protocol violations, unevaluable specimens, or the presence of type-specific sero-positive antibody at baseline.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 6 (n=87, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 11 (n=90, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 16 (n=90, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="3.7" lower_limit="0.1" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18 (n=90, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="90.6" upper_limit="99.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Anti-HPV Antibody Titers (cLIA)</title>
        <description>Geometric means of Type-specific Serum anti-HPV antibody titers (cLIA)</description>
        <time_frame>Arm A week 0, 28, 72, 96, 97, 100; Arm B week 0, 28, 72, 96, 97, 100, 124.</time_frame>
        <population>The type-specific results are reported for participants remaining after exclusion of those with protocol violations, unevaluable specimens, or the presence of type-specific sero-positive antibody at baseline as well as any participants with any missing values at any time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A QHPV</title>
            <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
          </group>
          <group group_id="O2">
            <title>Arm B Placebo/QHPV</title>
            <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Anti-HPV Antibody Titers (cLIA)</title>
          <description>Geometric means of Type-specific Serum anti-HPV antibody titers (cLIA)</description>
          <population>The type-specific results are reported for participants remaining after exclusion of those with protocol violations, unevaluable specimens, or the presence of type-specific sero-positive antibody at baseline as well as any participants with any missing values at any time points.</population>
          <units>milli-Merck units [mMU]/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 6 study entry (n=69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.5" upper_limit="4.1"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.4" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6 week 28 (n=69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544.2" lower_limit="395.4" upper_limit="749.1"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.7" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6 week 72 (n=69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.4" lower_limit="196.5" upper_limit="334.7"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.6" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6 week 96 (n=69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.9" lower_limit="167.3" upper_limit="310.3"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.6" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6 week 97 (n=69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1604.8" lower_limit="1162.0" upper_limit="2216.1"/>
                    <measurement group_id="O2" value="17.1" lower_limit="7.1" upper_limit="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6 week 100 (n=69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2473.6" lower_limit="1770.2" upper_limit="3456.4"/>
                    <measurement group_id="O2" value="79.7" lower_limit="43.7" upper_limit="145.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6 week 124 (n=0, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 124 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="678.8" lower_limit="396.4" upper_limit="1162.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 11 study entry (n=72, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.9" upper_limit="4.2"/>
                    <measurement group_id="O2" value="4.0" lower_limit="4.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 11 week 28 (n=72, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1396.6" lower_limit="1103.8" upper_limit="1767.1"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 11 week 72 (n=72, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.1" lower_limit="234.4" upper_limit="418.3"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.9" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 11 week 96 (n=72, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286.5" lower_limit="207.1" upper_limit="396.4"/>
                    <measurement group_id="O2" value="4.0" lower_limit="4.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 11 week 97 (n=72, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1931.7" lower_limit="1389.1" upper_limit="2686.3"/>
                    <measurement group_id="O2" value="11.8" lower_limit="5.5" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 11 week 100 (n=72, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3611.2" lower_limit="2746.8" upper_limit="4747.6"/>
                    <measurement group_id="O2" value="86.4" lower_limit="48.7" upper_limit="153.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 11 week 124 (n=0, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 124 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="1023.0" lower_limit="704.2" upper_limit="1486.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 16 study entry (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="5.5" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.5" lower_limit="5.5" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 16 week 28 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5172.5" lower_limit="3889.8" upper_limit="6878.2"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5.3" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 16 week 72 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1126.4" lower_limit="788.6" upper_limit="1609.0"/>
                    <measurement group_id="O2" value="5.5" lower_limit="5.5" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 16 week 96 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1034.5" lower_limit="708.8" upper_limit="1509.7"/>
                    <measurement group_id="O2" value="5.5" lower_limit="5.5" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 16 week 97 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6167.8" lower_limit="4391.8" upper_limit="8661.8"/>
                    <measurement group_id="O2" value="12.1" lower_limit="5.4" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 16 week 100 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11205.6" lower_limit="8184.7" upper_limit="15341.5"/>
                    <measurement group_id="O2" value="142.6" lower_limit="74.1" upper_limit="274.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 16 week 124 (n=0, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 124 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="4113.8" lower_limit="2404.2" upper_limit="7039.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18 study entry (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.9" upper_limit="5.3"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18 week 28 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="931.2" lower_limit="616.7" upper_limit="1406.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18 week 72 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.2" lower_limit="92.5" upper_limit="237.4"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18 week 96 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.0" lower_limit="86.6" upper_limit="232.8"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18 week 97 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="925.7" lower_limit="567.6" upper_limit="1510.0"/>
                    <measurement group_id="O2" value="7.1" lower_limit="4.6" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18 week 100 (n=71, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1530.7" lower_limit="991.7" upper_limit="2362.4"/>
                    <measurement group_id="O2" value="18.7" lower_limit="10.6" upper_limit="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18 week 124 (n=0, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 124 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="734.3" lower_limit="357.3" upper_limit="1508.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Count Over Time</title>
        <time_frame>Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.</time_frame>
        <population>Any participant who received at least one study vaccine/placebo and with non-missing CD4 counts.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A QHPV</title>
            <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
          </group>
          <group group_id="O2">
            <title>Arm B Placebo/QHPV</title>
            <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count Over Time</title>
          <population>Any participant who received at least one study vaccine/placebo and with non-missing CD4 counts.</population>
          <units>cells/µL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4 count at study entry (n=96, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="868" lower_limit="794" upper_limit="942"/>
                    <measurement group_id="O2" value="1013" lower_limit="843" upper_limit="1183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 8 (n=93, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="907" lower_limit="830" upper_limit="985"/>
                    <measurement group_id="O2" value="1018" lower_limit="851" upper_limit="1185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 12 (n=93, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="906" lower_limit="828" upper_limit="983"/>
                    <measurement group_id="O2" value="1056" lower_limit="830" upper_limit="1282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 24 (n=94, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="864" lower_limit="792" upper_limit="936"/>
                    <measurement group_id="O2" value="993" lower_limit="826" upper_limit="1160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 28 (n=95, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="875" lower_limit="800" upper_limit="950"/>
                    <measurement group_id="O2" value="959" lower_limit="803" upper_limit="1115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 72 (n=88, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823" lower_limit="746" upper_limit="900"/>
                    <measurement group_id="O2" value="933" lower_limit="768" upper_limit="1098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 96 (n=88, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="781" lower_limit="712" upper_limit="849"/>
                    <measurement group_id="O2" value="874" lower_limit="718" upper_limit="1031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 100 (n=85, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831" lower_limit="754" upper_limit="907"/>
                    <measurement group_id="O2" value="924" lower_limit="766" upper_limit="1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 104 (n=0, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="929" lower_limit="776" upper_limit="1082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 108 (n=82, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839" lower_limit="757" upper_limit="921"/>
                    <measurement group_id="O2" value="980" lower_limit="786" upper_limit="1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 120 (n=0, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 120 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="931" lower_limit="745" upper_limit="1117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count at week 124 (n=0, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 124 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="920" lower_limit="728" upper_limit="1112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Percent Over Time</title>
        <time_frame>Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.</time_frame>
        <population>Any participant who received at least one study vaccine/placebo and with non-missing CD4%.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A QHPV</title>
            <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
          </group>
          <group group_id="O2">
            <title>Arm B Placebo/QHPV</title>
            <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Percent Over Time</title>
          <population>Any participant who received at least one study vaccine/placebo and with non-missing CD4%.</population>
          <units>percentage of total lymphocytes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4 percent at study entry (n=96, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="32" upper_limit="35"/>
                    <measurement group_id="O2" value="36" lower_limit="33" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 8 (n=93, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="32" upper_limit="35"/>
                    <measurement group_id="O2" value="36" lower_limit="33" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 12 (n=93, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="33" upper_limit="37"/>
                    <measurement group_id="O2" value="37" lower_limit="33" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 24 (n=94, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="33" upper_limit="36"/>
                    <measurement group_id="O2" value="35" lower_limit="31" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 28 (n=95, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="33" upper_limit="36"/>
                    <measurement group_id="O2" value="34" lower_limit="31" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 72 (n=88, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="32" upper_limit="35"/>
                    <measurement group_id="O2" value="34" lower_limit="30" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 96 (n=88, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="32" upper_limit="35"/>
                    <measurement group_id="O2" value="34" lower_limit="30" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 100 (n=85, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="33" upper_limit="37"/>
                    <measurement group_id="O2" value="35" lower_limit="32" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 104 (n=0, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="36" lower_limit="32" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 108 (n=82, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="33" upper_limit="37"/>
                    <measurement group_id="O2" value="34" lower_limit="30" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 120 (n=0, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 120 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="37" lower_limit="32" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 percent at week 124 (n=0, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 124 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="35" lower_limit="31" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 Viral Load (Ribonucleic Acid [RNA] Copies/ml) Over Time</title>
        <time_frame>Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.</time_frame>
        <population>Any participant who received at least one study vaccine/placebo and with non-missing HIV-1 viral load.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A QHPV</title>
            <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
          </group>
          <group group_id="O2">
            <title>Arm B Placebo/QHPV</title>
            <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Viral Load (Ribonucleic Acid [RNA] Copies/ml) Over Time</title>
          <population>Any participant who received at least one study vaccine/placebo and with non-missing HIV-1 viral load.</population>
          <units>Log10(copies/mL)</units>
          <param>Log Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Log10(RNA) at study entry (n=96, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.5" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.3" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 8 (n=92, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.6" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.5" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 12 (n=93, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.6" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.5" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 24 (n=94, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.6" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.4" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 28 (n=95, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.6" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.4" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 72 (n=87, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.5" upper_limit="2.8"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.4" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 96 (n=88, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.4" upper_limit="2.8"/>
                    <measurement group_id="O2" value="2.4" lower_limit="2.1" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 100 (n=84, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.4" upper_limit="2.8"/>
                    <measurement group_id="O2" value="2.4" lower_limit="2.1" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 104 (n=0, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="2.4" lower_limit="2.0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 108 (n=87, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.4" upper_limit="2.7"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.1" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 120 (n=0, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 120 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="2.3" lower_limit="2.0" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log10(RNA) at week 124 (n=0, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 124 is not a designated time point for Arm A.</measurement>
                    <measurement group_id="O2" value="2.3" lower_limit="1.9" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the time when participants started to receive study treatment until study completion and before August 10, 2009 (primary completion date).</time_frame>
      <desc>Expedited adverse event (AE) reporting followed Intensive Division of AIDS (DAIDS) Reporting Level, which included AEs resulting in death, congenital anomalies, fetal losses, significant disabilities, requiring hospitalization, and &gt;=grade 3 AEs defined by the &quot;DAIDS Table for Grading the Severity of Adult and Pediatric AEs&quot;, V1.0, 12/2004.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A QHPV</title>
          <description>Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.</description>
        </group>
        <group group_id="E2">
          <title>Arm B Placebo/QHPV</title>
          <description>Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood albumin abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate abnormal</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and Merck &amp; Co., Inc., NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinicaltrials.gov Coordinator</name_or_title>
      <organization>Center for Biostatistics in AIDS Research, Harvard School of Public Health</organization>
      <phone>(617) 432-2829</phone>
      <email>CBAR.ClinicalTrials.Gov@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

